X

Trial Profile

A First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677 in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Aug 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mazdutide (Primary)
Indications Unspecified
Focus Adverse reactions; First in man
Sponsors Eli Lilly and Company

Most Recent Events

29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association
21 Jul 2017 Status changed from active, no longer recruiting to completed.
19 Jun 2017 Planned End Date changed from 14 Jun 2017 to 14 Jul 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com